Cargando…
Matrix-metalloproteinase-2, -8 and -9 in serum and skin blister fluid in patients with severe sepsis
INTRODUCTION: Matrix metalloproteinases (MMPs) have various roles in inflammatory states. They seem to be able to modulate endothelial barriers and regulate the activity of chemokines and cytokines. The timely development of the levels during severe sepsis and thereafter have not been investigated....
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2887163/ https://www.ncbi.nlm.nih.gov/pubmed/20356362 http://dx.doi.org/10.1186/cc8938 |
_version_ | 1782182518197321728 |
---|---|
author | Gäddnäs, Fiia P Sutinen, Meeri M Koskela, Marjo Tervahartiala, Taina Sorsa, Timo Salo, Tuula A Laurila, Jouko J Koivukangas, Vesa Ala-Kokko, Tero I Oikarinen, Aarne |
author_facet | Gäddnäs, Fiia P Sutinen, Meeri M Koskela, Marjo Tervahartiala, Taina Sorsa, Timo Salo, Tuula A Laurila, Jouko J Koivukangas, Vesa Ala-Kokko, Tero I Oikarinen, Aarne |
author_sort | Gäddnäs, Fiia P |
collection | PubMed |
description | INTRODUCTION: Matrix metalloproteinases (MMPs) have various roles in inflammatory states. They seem to be able to modulate endothelial barriers and regulate the activity of chemokines and cytokines. The timely development of the levels during severe sepsis and thereafter have not been investigated. In addition it was of interest to study alterations of MMP-levels in intact skin, as the skin is the largest barrier against external pathogens and MMPs have not been studied at organ level in human sepsis. The aim of this study was to investigate the timely development of serum and skin MMP-2, -8 and -9 levels in human severe sepsis and their association with disease severity and mortality. METHODS: Forty-four patients with severe sepsis and fifteen healthy controls were included in this prospective longitudinal study. The amounts of MMP-2, -8 and -9 were analyzed from serum at days 1, 4, 6, 8, and 10, and from skin suction blister fluid at days 1 and 5 from the beginning of severe sepsis. Additionally, samples from the survivors were obtained after three and six months. RESULTS: The levels of MMP-2 and -8 were up-regulated in severe sepsis in comparison to healthy controls in skin blister fluid and serum. Compared to the controls MMP-9 levels were lower in sepsis from the fourth day on in serum and both the first and fifth day in skin blister fluid. Active forms of MMP-2 and -9 were present only in severe sepsis. The non-survivors had higher pro- and active MMP-2 levels than the survivors in skin blister fluid samples. Furthermore, MMP-2 levels were more pronounced in blister fluid and serum samples in patients with more severe organ failures. In the survivors at 3 and 6 month follow-up the MMP levels had returned to normal. CONCLUSIONS: MMP-2 and -8 are elevated in serum and blister fluid in severe sepsis, implying that they may play a significant role in the pathogenesis of severe sepsis and organ dysfunctions. Active forms of MMP-2 and 9 were only present in patients with severe sepsis, and higher MMP-2 levels in skin blister and serum were associated with more severe organ dysfunctions. |
format | Text |
id | pubmed-2887163 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-28871632010-06-18 Matrix-metalloproteinase-2, -8 and -9 in serum and skin blister fluid in patients with severe sepsis Gäddnäs, Fiia P Sutinen, Meeri M Koskela, Marjo Tervahartiala, Taina Sorsa, Timo Salo, Tuula A Laurila, Jouko J Koivukangas, Vesa Ala-Kokko, Tero I Oikarinen, Aarne Crit Care Research INTRODUCTION: Matrix metalloproteinases (MMPs) have various roles in inflammatory states. They seem to be able to modulate endothelial barriers and regulate the activity of chemokines and cytokines. The timely development of the levels during severe sepsis and thereafter have not been investigated. In addition it was of interest to study alterations of MMP-levels in intact skin, as the skin is the largest barrier against external pathogens and MMPs have not been studied at organ level in human sepsis. The aim of this study was to investigate the timely development of serum and skin MMP-2, -8 and -9 levels in human severe sepsis and their association with disease severity and mortality. METHODS: Forty-four patients with severe sepsis and fifteen healthy controls were included in this prospective longitudinal study. The amounts of MMP-2, -8 and -9 were analyzed from serum at days 1, 4, 6, 8, and 10, and from skin suction blister fluid at days 1 and 5 from the beginning of severe sepsis. Additionally, samples from the survivors were obtained after three and six months. RESULTS: The levels of MMP-2 and -8 were up-regulated in severe sepsis in comparison to healthy controls in skin blister fluid and serum. Compared to the controls MMP-9 levels were lower in sepsis from the fourth day on in serum and both the first and fifth day in skin blister fluid. Active forms of MMP-2 and -9 were present only in severe sepsis. The non-survivors had higher pro- and active MMP-2 levels than the survivors in skin blister fluid samples. Furthermore, MMP-2 levels were more pronounced in blister fluid and serum samples in patients with more severe organ failures. In the survivors at 3 and 6 month follow-up the MMP levels had returned to normal. CONCLUSIONS: MMP-2 and -8 are elevated in serum and blister fluid in severe sepsis, implying that they may play a significant role in the pathogenesis of severe sepsis and organ dysfunctions. Active forms of MMP-2 and 9 were only present in patients with severe sepsis, and higher MMP-2 levels in skin blister and serum were associated with more severe organ dysfunctions. BioMed Central 2010 2010-03-31 /pmc/articles/PMC2887163/ /pubmed/20356362 http://dx.doi.org/10.1186/cc8938 Text en Copyright ©2010 Gäddnäs et al.; licensee Biomed Central, Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons attribution license (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Gäddnäs, Fiia P Sutinen, Meeri M Koskela, Marjo Tervahartiala, Taina Sorsa, Timo Salo, Tuula A Laurila, Jouko J Koivukangas, Vesa Ala-Kokko, Tero I Oikarinen, Aarne Matrix-metalloproteinase-2, -8 and -9 in serum and skin blister fluid in patients with severe sepsis |
title | Matrix-metalloproteinase-2, -8 and -9 in serum and skin blister fluid in patients with severe sepsis |
title_full | Matrix-metalloproteinase-2, -8 and -9 in serum and skin blister fluid in patients with severe sepsis |
title_fullStr | Matrix-metalloproteinase-2, -8 and -9 in serum and skin blister fluid in patients with severe sepsis |
title_full_unstemmed | Matrix-metalloproteinase-2, -8 and -9 in serum and skin blister fluid in patients with severe sepsis |
title_short | Matrix-metalloproteinase-2, -8 and -9 in serum and skin blister fluid in patients with severe sepsis |
title_sort | matrix-metalloproteinase-2, -8 and -9 in serum and skin blister fluid in patients with severe sepsis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2887163/ https://www.ncbi.nlm.nih.gov/pubmed/20356362 http://dx.doi.org/10.1186/cc8938 |
work_keys_str_mv | AT gaddnasfiiap matrixmetalloproteinase28and9inserumandskinblisterfluidinpatientswithseveresepsis AT sutinenmeerim matrixmetalloproteinase28and9inserumandskinblisterfluidinpatientswithseveresepsis AT koskelamarjo matrixmetalloproteinase28and9inserumandskinblisterfluidinpatientswithseveresepsis AT tervahartialataina matrixmetalloproteinase28and9inserumandskinblisterfluidinpatientswithseveresepsis AT sorsatimo matrixmetalloproteinase28and9inserumandskinblisterfluidinpatientswithseveresepsis AT salotuulaa matrixmetalloproteinase28and9inserumandskinblisterfluidinpatientswithseveresepsis AT laurilajoukoj matrixmetalloproteinase28and9inserumandskinblisterfluidinpatientswithseveresepsis AT koivukangasvesa matrixmetalloproteinase28and9inserumandskinblisterfluidinpatientswithseveresepsis AT alakokkoteroi matrixmetalloproteinase28and9inserumandskinblisterfluidinpatientswithseveresepsis AT oikarinenaarne matrixmetalloproteinase28and9inserumandskinblisterfluidinpatientswithseveresepsis |